Systemic delivery of a monoclonal antibody that inhibits myostatin in a mouse model of OPMD improved the body and muscle mass, increased the muscle strength and the myofiber diameter, and reduced the expression of fibrosis markers, although no effect on intranuclear inclusions was observed [54]. The gene discussed is MSTN; the disease is oculopharyngeal muscular dystrophy.